Uveitis is a condition characterized by inflammation of the uvea, which includes the iris, ciliary body, and choroid. Treatment of uveitis often involves anti-inflammatory medications, immunosuppressive drugs, and, in some cases, surgery.
Latest Uveitis Treatment Companies Update
November 2023: ABIONYX Pharma, a recently established biotechnology company, focused on the exploration and advancement of novel therapies utilizing recombinant human apoA-1, the only known substance of its kind. The company has recently disclosed encouraging findings in the field of ophthalmology regarding the initial group of CER-001-based biopharmaceuticals, which hold promise for addressing ocular pathologies. This study presents novel findings on the long-term effectiveness of CER-001 following a solitary intraocular delivery in a uveitis paradigm characterized by intense inflammation. In light of the positive clinical outcomes observed in a patient with LCAT deficiency, who experienced the resolution of visual blurring associated with corneal deposits following treatment under a Temporary Authorization for Use, and the sustained improvement in visual function over a period exceeding one year, ABIONYX Pharma undertook additional preclinical investigations in the field of ophthalmology.
August 2023: Tarsier Pharma, a biotechnology firm at an advanced clinical stage, has been working on the development of dazdotuftide (formerly referred to as TRS), which is a New Chemical Entity targeting patients with immune-mediated disorders. The business recently disclosed the findings from the TRS4VISION Trial, which focused on noninfectious anterior uveitis. Although the primary objective was not achieved, a further review of the data reveals the highly expected clinical characteristics of a combination therapy that effectively addresses both safety concerns and the resolution of inflammation. This has significant potential for the treatment of noninfectious uveitis, particularly in the context of uveitic glaucoma. The TRS4Vision study was a randomized, multi-center, active-controlled, double-masked clinical trial conducted to assess the safety and effectiveness of TRS01 eye drops in the management of individuals with active noninfectious anterior uveitis, including those with uveitic glaucoma.
Uveitis Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)